Virus News and Research

Latest Virus News and Research

Richmont obtains PURE's IV-7 Germ Defense disinfectant registration in South Africa

PURE Bioscience, creator of the patented silver dihydrogen citrate antimicrobial, today announced that its marketing partner, Richmont Sciences, LLC, through its distributor, Bio Care Products Ltd. of Lanseria, has obtained registration of PURE's SDC-based IV-7 Ultimate Germ Defense disinfectant for use on all inanimate surfaces by the South African National Regulator for Compulsory Specifications.

18 Mar 2011

Rubini black elderberry extract can inhibit flu and respiratory tract infections

Historically, black elderberries were among the most regarded folk remedies for coughs, colds, and flu. Now modern science has authenticated these therapeutic properties. In February 2011, researchers at Justus-Liebig University in Geissen, Germany reported that a concentrated liquid extract of black elderberries, commercially available as Rubini - Elderberry Extract 3.2%, inhibited the growth of influenza A and B viruses and bacteria associated with upper respiratory tract infections.

18 Mar 2011

Longer looks: Health policy picks that will fascinate, captivate

Thirty-four states have some type of HIV-criminalization law. Depending on the state, it may be illegal to expose someone else to HIV, transmit the virus or conceal your own HIV-positive status from potential sexual partners. This criminalization extends even to cases in which condoms were used or when the virus was not transmitted, as well as to acts, such as spitting or biting, that pose minuscule to no risk.

18 Mar 2011

Alnylam to defend against Tekmira complaint

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, is reporting the filing of a complaint by Tekmira Pharmaceuticals Corporation in the Business Litigation Session (BLS) of the Massachusetts Superior Court. The complaint alleges misappropriation and misuse of information, amongst other allegations.

18 Mar 2011

Nationwide observance raises awareness about HIV/AIDS spread in women

National Women and Girls AIDS Awareness Day, a nationwide observance that raises awareness and promotes action in the fight against HIV/AIDS, took place on March 10.

17 Mar 2011

Inovio signs agreement with OncoSec to sell non-DNA cancer vaccine technology

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has signed an agreement with OncoSec Medical Inc. providing for the sale to OncoSec of certain non-DNA vaccine technology and intellectual property relating to electroporation technology useful for electrochemical and cytokine based immune therapies for treating solid tumors.

17 Mar 2011

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

PsiOxus Therapeutics, Ltd. announced initiation of a Phase II study of MT-102, a small molecule therapeutic for the treatment of cancer- and age-related wasting. MT-102 is being developed to reverse the effects of cachexia, a wasting disease that accompanies cancer, heart failure, COPD, renal failure, cirrhosis and rheumatoid arthritis, and that is associated with significant morbidity and mortality.

17 Mar 2011

Research highlights new parameters for HIV study

A research article co-authored by Brenna Anderson, MD, director of Reproductive Infectious Diseases Consultation in the Division of Maternal-Fetal Medicine at Women & Infants Hospital of Rhode Island, was included in the recently published special issue of the American Journal of Reproductive Immunology.

17 Mar 2011

Scientists to develop new universal vaccine against various flu viruses

A vaccine that helps against all types of influenza - for several years? If all goes right for Norwegian company Bionor Pharma ASA, such a vaccine could exist within a few years.

17 Mar 2011

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Neurologix, Inc., announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease were published in an online-first edition of The Lancet Neurology.

17 Mar 2011

Results from first successful phase 2 trial of gene therapy for Parkinson's or any neurologic disorder

A gene therapy called NLX-P101 dramatically reduces movement impairment in Parkinson's patients, according to results of a Phase 2 study published today in the journal Lancet Neurology. The approach introduces a gene into the brain to normalize chemical signaling.

16 Mar 2011

Research: Underweight HCV-infected patients tend to be older at HCC onset

The incidence and mortality associated with hepatocellular carcinoma have been increasing worldwide, and hepatitis C virus infection plays an important role in the pathogenesis of HCC.

16 Mar 2011

First ever light-activated, non-surgical treatment for HPV and pre-cancerous lesions of the cervix

A new non-surgical, tissue-preserving therapeutic procedure is being developed to more effectively remove HPV infection and treat precursors of cervical cancer.

16 Mar 2011

Elite controllers' T cells resist HIV-1 infection by selective upregulation of protein p21

In the years since the AIDS epidemic began, it has become clear that there is substantial variation in the way that individuals respond to HIV infection. Although most progress quickly from initial infection to immunodeficiency, a small subset survive for long periods without developing symptoms.

16 Mar 2011

Experimental vaccine against human norovirus generates strong, safe immune response in mice

Scientists have shown that an experimental vaccine against the human norovirus - the bug behind about 90 percent of highly contagious nonbacterial illnesses that cause diarrhea and vomiting - can generate a strong immune response in mice without appearing to cause the animals any harm.

16 Mar 2011

Global settlement agreement reached in Tuschl patents litigation

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced the signing of a global settlement agreement among Alnylam, Max Planck Society ("Max Planck"), the Whitehead Institute for Biomedical Research ("Whitehead") and the University of Massachusetts ("UMass") resolving their ongoing litigation regarding the Tuschl patents.

16 Mar 2011

BRAF gene defect leads to pilocytic astrocytoma in children

Pilocytic astrocytoma, the most common brain tumor in children, is usually slow-growing and benign. However, surgeons often cannot completely remove the diffusely growing tumor.

16 Mar 2011

Self-sample HPV test can help increase cervical screening uptake among women

Home tests for the human papillomavirus could help increase the take-up of cervical screening among women who do not respond to screening invitations, new research shows today.

16 Mar 2011

FDA clears Intralytix phage-based EcoShield food safety product

Intralytix, Inc. announced today that it has received regulatory clearance from the Food and Drug Administration for its phage-based EcoShield food safety product, effective against E. coli O157:H7.

16 Mar 2011

iTherX commences ITX-5061 Phase 1b study in patients with HCV

iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that it has commenced patient recruitment in an open-label, proof-of-concept Phase 1b study of its lead compound ITX-5061 in liver transplant patients with hepatitis C virus infection.

16 Mar 2011

Virus News and Research

Latest Virus News and Research

Richmont obtains PURE's IV-7 Germ Defense disinfectant registration in South Africa

Rubini black elderberry extract can inhibit flu and respiratory tract infections

Longer looks: Health policy picks that will fascinate, captivate

Alnylam to defend against Tekmira complaint

Nationwide observance raises awareness about HIV/AIDS spread in women

Inovio signs agreement with OncoSec to sell non-DNA cancer vaccine technology

PsiOxus commences MT-102 Phase II study for treatment of cancer- and age-related wasting

Research highlights new parameters for HIV study

Scientists to develop new universal vaccine against various flu viruses

The Lancet Neurology publishes Neurologix NLX-P101 Phase 2 trial results against PD

Results from first successful phase 2 trial of gene therapy for Parkinson's or any neurologic disorder

Research: Underweight HCV-infected patients tend to be older at HCC onset

First ever light-activated, non-surgical treatment for HPV and pre-cancerous lesions of the cervix

Elite controllers' T cells resist HIV-1 infection by selective upregulation of protein p21

Experimental vaccine against human norovirus generates strong, safe immune response in mice

Global settlement agreement reached in Tuschl patents litigation

BRAF gene defect leads to pilocytic astrocytoma in children

Self-sample HPV test can help increase cervical screening uptake among women

FDA clears Intralytix phage-based EcoShield food safety product

iTherX commences ITX-5061 Phase 1b study in patients with HCV

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in